Back to top

BeOne Medicines Ltd (6160) Receives a Buy from UBS

UBS analyst maintained a Buy rating on BeOne Medicines Ltd on July 23 and set a price target of HK$273.60. The company’s shares closed yesterday at...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BeOne Medicines Ltd. - Sponsored ADR (ONC)